American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
-
Am J Health Syst Pharm · Jan 2019
Case ReportsMidodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis.
Use of the vasodilator midodrine for the treatment of treprostinil-induced hypotension is reported. ⋯ A 49-year-old patient tolerated 60-mg daily doses of midodrine along with 30-mg intradialytic doses for the management of treprostinil-induced hypotension and prevention of HD interruption, without adverse effects.
-
Am J Health Syst Pharm · Dec 2018
Longitudinal trends in U.S. shortages of sterile solutions, 2001-17.
Trends in the shortages of sterile solutions in the United States were evaluated. ⋯ There were 37 shortages of sterile solutions from 2001 through 2017. Shortages became more severe after Hurricane Maria damaged manufacturing facilities in Puerto Rico, with 12 new shortages reported in 2017.
-
Am J Health Syst Pharm · Dec 2018
Case ReportsEffect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels.
The effect of therapeutic plasma exchange (TPE) on antifactor Xa activity in a patient treated with enoxaparin and levetiracetam is reported. ⋯ In a patient receiving TPE to manage anti-MDA5 antibody ILD associated with dermatomyositis and a prior seizure, TPE significantly altered enoxaparin antifactor Xa activity as evidenced by the undetectable antifactor Xa activity level drawn after TPE. Alternatively, TPE had a minimal effect on the clearance of levetiracetam as evidenced by the post-TPE level and fraction elimination of only 5% of total body stores.
-
Am J Health Syst Pharm · Nov 2018
Development of an operational productivity tool within a cancer treatment center pharmacy.
The development and implementation of an operational productivity tool in an academic cancer treatment center are described. ⋯ The productivity data provided precise information to assess trends in operations within the pharmacy of an outpatient cancer treatment center.
-
Am J Health Syst Pharm · Sep 2018
ReviewClinical update on thrombolytic use in pulmonary embolism: A focus on intermediate-risk patients.
Current literature on clinical controversies surrounding the use of thrombolytic agents in patients with intermediate-risk pulmonary embolism (PE) is reviewed. ⋯ The use of thrombolysis in the treatment of intermediate-risk PE is complicated by high rates of bleeding and should be limited to patients who clinically deteriorate rather than given as a standard-of-care treatment in this population. Data for low-dose thrombolysis remain limited.